Toxicology, Trials, and Triumphs
Dr. Lauren Mihalcik (CBE ‘98)
Dr. Lauren Mihalcik, Vice President, Toxicology, at Aclairo Pharmaceutical Development Group, initially worked at the NIH, screening molecules for epilepsy. She transitioned to the FDA as a non-clinical reviewer, analyzing pharmacology, toxicology, and safety for clinical trials. Falling in love with toxicology, she later joined Amgen as a toxicologist, where she managed drug development in a team setting. After moving into consulting, she now advises on clinical trial study design, ensuring safety, compliance with FDA regulations, and risk analysis. With over 20 years of experience, she recently contributed to successful gene therapy approvals and biosimilar programs.
3 sectors: Government, Corporate, and Private
Dr. Mihalcik’s career reflects the diverse opportunities within government, corporate, and private sectors of the pharmaceutical industry. Starting at the NIH, she worked in a government setting, focusing on research and molecular screening for conditions like epilepsy. This role allowed her to explore the intersection of pharmacology and medicinal chemistry while providing foundational knowledge. Moving to the FDA, she transitioned to a regulatory role, reviewing clinical trial data to ensure safety and compliance, with an emphasis on risk analysis and public health.
In the corporate sector, Dr. Mihalcik joined Amgen as a toxicologist, where she contributed to drug development in a team-oriented, fast-paced environment. The corporate world offered a structured setting to manage large-scale drug programs and facilitated her passion for translating research into therapies. Later, she moved to the private consulting sector, advising companies on clinical trial designs, safety protocols, and FDA approval strategies. Here, she assists clients in navigating the complexities of drug development, ensuring that safety and regulatory standards align with the goal of bringing effective treatments to market.
Each sector offers unique challenges and rewards: government work emphasizes public health and research, corporate settings foster collaborative drug development, and the private sector offers flexibility and specialized expertise for clients navigating regulatory processes.
Defining Success
In the pharmaceutical industry, assessing risk is key in drug development. Dr. Mihalcik’s experience shows how risk assessment evaluates safety, efficacy, and potential side effects, ensuring drugs are safe for human use. At the FDA, she analyzed pharmacology, pharmacokinetics, and toxicology data to identify hazards during clinical trials. This includes understanding drug behavior in animal models to predict human effects—crucial for preventing harmful side effects like cancer or organ damage. Risk assessment identifies dangers and determines acceptable risks, balancing potential benefits to patients.
Success in this field is multifaceted. On a regulatory level, it means ensuring a drug's safety and approval. Given the challenges of drug development, success is o en defined by incremental achievements, vital for balancing effective treatments with team growth. Ultimately, successful risk assessment in drug development ensures that new treatments are both safe and effective, while navigating the challenges of time, cost, and regulatory requirements to benefit patients and support the teams behind the innovations.
Alec Silberg (MOL '28)
